A detailed history of Eversept Partners, LP transactions in Nevro Corp stock. As of the latest transaction made, Eversept Partners, LP holds 313,780 shares of NVRO stock, worth $1.42 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
313,780
Previous 499,395 37.17%
Holding current value
$1.42 Million
Previous $4.2 Million 58.37%
% of portfolio
0.14%
Previous 0.32%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.71 - $10.1 $874,246 - $1.87 Million
-185,615 Reduced 37.17%
313,780 $1.75 Million
Q2 2024

Aug 14, 2024

BUY
$7.96 - $13.59 $873,466 - $1.49 Million
109,732 Added 28.16%
499,395 $4.2 Million
Q1 2024

May 15, 2024

BUY
$13.56 - $20.78 $5.28 Million - $8.1 Million
389,663 New
389,663 $5.63 Million
Q1 2022

May 16, 2022

SELL
$59.95 - $92.06 $3.96 Million - $6.08 Million
-66,074 Closed
0 $0
Q4 2021

Nov 08, 2023

BUY
$81.07 - $121.29 $5.36 Million - $8.01 Million
66,074 New
66,074 $5.36 Million
Q4 2021

Feb 14, 2022

BUY
$81.07 - $121.29 $5.36 Million - $8.01 Million
66,074 New
66,074 $5.36 Million
Q3 2018

Nov 14, 2018

SELL
$44.22 - $75.47 $2.09 Million - $3.57 Million
-47,279 Closed
0 $0
Q2 2018

Nov 08, 2023

SELL
$72.38 - $92.5 $982,268 - $1.26 Million
-13,571 Reduced 22.3%
47,279 $3.78 Million
Q2 2018

Aug 14, 2018

SELL
$72.38 - $92.5 $982,268 - $1.26 Million
-13,571 Reduced 22.3%
47,279 $3.78 Million
Q1 2018

Nov 08, 2023

BUY
$69.46 - $88.57 $4.23 Million - $5.39 Million
60,850 New
60,850 $5.27 Billion
Q1 2018

May 14, 2018

SELL
$69.46 - $88.57 $277,840 - $354,280
-4,000 Reduced 6.17%
60,850 $5.27 Million
Q4 2017

Nov 08, 2023

BUY
$65.94 - $93.31 $4.28 Million - $6.05 Million
64,850 New
64,850 $4.48 Billion
Q4 2017

Feb 12, 2018

BUY
$65.94 - $93.31 $4.28 Million - $6.05 Million
64,850
64,850 $4.48 Million

Others Institutions Holding NVRO

About NEVRO CORP


  • Ticker NVRO
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 35,387,800
  • Market Cap $160M
  • Description
  • Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...
More about NVRO
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.